Internal Medicine, Endocrinology, Diabetes, & Metabolism · Limerick, PA
NPI
1215079330
Since 2007
Specialty
Internal Medicine, Endocrinology, Diabetes, & Metabolism
Code 207RE0101X
Group practices
1
Medicare group memberships
Hospitals
5
Hospital affiliations
410 W Linfield Trappe Rd Ste 100
Limerick, PA, 19468
Phone (610) 495-2300
Groups this clinician bills Medicare through
Medicare paid, 2024
$327K
20,914 services
Medicare patients, 2024
629
Average age 73
Drug cost, 2024
$4.6M
11,242 prescriptions
Company payments, 2025
$106
From 2 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Somera Ali was code J3111 (injection, romosozumab-aqqg, 1 mg), 5,460 times for 12 patients. In total Somera Ali billed 20,914 services in 27 codes, and Medicare paid $327K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2022-02-11.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J3111 Injection, romosozumab-aqqg, 1 mg | Office | 5,460 | 12 | $8.18 | $45K |
| J0897 Injection, denosumab, 1 mg | Office | 2,400 | 40 | $19.32 | $46K |
| J1745 Injection, infliximab, excludes biosimilar, 10 mg | Office | 2,070 | 14 | $24.66 | $51K |
| 99214 Office E&M - Established | Office | 802 | 435 | $92.39 | $74K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 507 | 389 | $12.50 | $6,336 |
| 95251 Test - Miscellaneous | Office | 306 | 163 | $26.28 | $8,040 |
| 96372 Injection Administration | Office | 90 | 57 | $11.43 | $1,029 |
| 99213 Office E&M - Established | Office | 83 | 78 | $60.80 | $5,047 |
| 96413 Chemotherapy Administration | Office | 39 | 17 | $105.93 | $4,131 |
| 99204 Office E&M - New | Office | 37 | 37 | $125.86 | $4,657 |
| 96415 Chemotherapy Administration | Office | 35 | 14 | $22.60 | $791 |
| 83036 Blood Count | Office | 27 | 26 | $9.52 | $257 |
| 99203 Office E&M - New | Office | 20 | 20 | $64.20 | $1,284 |
By year: 2022 $321K for 20,775 services; 2023 $531K for 39,023 services; 2024 $327K for 20,914 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 83036 Blood Count | 27 | 26 | $9.52 | $257 |
Medicare prescription drug claims, 2024
In 2024, the drug Somera Ali prescribed most often to Medicare patients was Levothyroxine Sodium, with 794 prescriptions and refills. In total Somera Ali wrote 11,242 Medicare prescriptions that cost $4.6M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Levothyroxine Sodium Generic | 794 | 1,939 | 187 | $9,375 |
| Metformin Hcl Generic | 782 | 2,112 | 211 | $8,393 |
| Jardiance Empagliflozin | 752 | 1,413 | 145 | $807K |
| Ozempic Semaglutide | 695 | 1,005 | 124 | $940K |
| Lantus Solostar Insulin Glargine,hum.Rec.Anlog | 672 | 1,243 | 170 | $120K |
| Glimepiride Generic | 597 | 1,617 | 170 | $8,389 |
| Mounjaro Tirzepatide | 486 | 611 | 77 | $636K |
| Nano 2nd Gen Pen Needle Pen Needle, Diabetic | 454 | 1,139 | 170 | $46K |
| Novolog Flexpen Insulin Aspart | 353 | 682 | 105 | $100K |
| Repaglinide Generic | 322 | 774 | 91 | $12K |
| Metformin Hcl Er Metformin Hcl | 321 | 880 | 88 | $3,609 |
| Januvia Sitagliptin Phosphate | 269 | 501 | 56 | $257K |
| Farxiga Dapagliflozin Propanediol | 264 | 523 | 57 | $276K |
| Synthroid Levothyroxine Sodium | 260 | 678 | 64 | $18K |
| Basaglar Kwikpen U-100 Insulin Glargine,hum.Rec.Anlog | 206 | 345 | 43 | $112K |
Brand drugs: 5,885 claims; generic drugs: 4,459 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Somera Ali $106 ($106 in general payments such as food, travel and fees) from 2 companies. The largest payer was Abbott Laboratories with $89.39.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.